All participants are necessary to reach the project’s overall objective and they all contribute equally to the project in terms of person-months. Their expertise is synergistic and covers all the required scientific and technological knowledge. This is valuable in terms of knowledge transfer since the minimum overlap between the participants will maximise the value of the exchanged knowledge. Indeed, each participant’s contribution in the planned activities in terms of content and expertise provided, showing that: (i) that every participant is particularly suited for their allocated tasks, (ii) that their capacity will be further strengthened via planned intersectoral visits, and (iii) that they are all required to reach the project’s objective. It is important to note that the participants represent a viable supply chain that can develop the prototype post project and launch the product in the market. In this regard, the experience of Inocure, Imedica, and Artia will be vital as they have been previously involved in the development of biopharmaceuticals such as the proposed nanoBAT.
One of the main research institutions in Belgium. It is known for its strong tradition for quality assurance of its research. The research team owns a standard of care for specific pathogen free facility for housing animals at the Department of Pharmaceutical Chemistry and Drug Analysis. The laboratories are fully equipped to perform biochemical and cell biological assays encompassing area for protein expression analysis, histological equipment, HPLC, animal microdialysis for neurotransmitter analysis, hormones and blood indices analysis.
One of the world's oldest Universities and the first School of Medicine in history. It is the main research institution in the Veneto Region and one of the most important in Italy. The basic research laboratories comprise all facilities for biological sample analysis, tissue isolation and cell culture, chemical and biochemical analyses, nucleic acids isolation, qRT-PCR and WB analyses, histological and immunohistochemical analyses, laboratory animal housing; the clinical research laboratory includes all equipment for metabolic evaluations (body composition, energy expenditure, heat production).
InoCure s.r.o. is a SME focused on development of advanced nanomaterials for life science use. We are developing drug delivery and scaffolding systems based on nano/microparticles (μSphere technology) and nanofibrous systems (InoMATRIX technology). We help our partners design next generation of drug delivery systems and introduce those into mass production.
Specializes in the commercialization of pharmaceutical products (i.e. import/export, wholesale and distribution), market analysis, pharmaceutical marketing and distribution strategies. IMED also contains a research facility that aims to conduct implement edge technology in medical science and conduct clinical research in the pharmaceutical field (e.g. pharmacokinetics). Full range of labs for drug development, immunotoxicology, and pharmacokinetics.
“This project has received funding from the European Union’s Horizon 2020 research and innovation
programme under the Marie Skłodowska-Curie grant agreement No 691061”
We are a leading research, commercialization and engineering advisory company located in Athens, Greece, focusing on technology transfer and applied research, especially in the field of nanotechnology and advanced materials. Our efforts focus towards two main directions:
- oriented research and development of nanomaterials, nanocoatings, nanoelectronics and nanosensors as well as characterization of their structure and properties;
- providing engineering services in nanotechnology issues and in European and transnational funding.